Latest Replikins Ltd. Stories
LONDON, April 18, 2013 /PRNewswire/ -- Replikins Ltd will reveal details on the availability of two completely synthetic vaccine candidates, both with long-term prevention goals and acute short-term blocking capacity. One of these vaccines targets H7N9 alone, the other for H7N9 plus the other common influenza strains. The company is exploring partnerships with established healthcare and pharmaceutical companies to aggressively commercialize the technology. Because Replikins is...
LONDON, April 9, 2013 /PRNewswire/ -- Bioradar UK Ltd and Replikins Ltd announced today that a new completely synthetic H7N9 Replikins Vaccine is ready for testing. The news comes on the heels of four new cases of avian flu (H7N9) reported in China, bringing the total to 28 cases, 8 of whom have died from the virus. The new vaccine is produced without any biological substances and will be used without adjuvants, similar to the H5N1 Synthetic Replikins Vaccine which was found...
Will H7N9 Follow Limited Course of SARS or Longer Course of H1N1 Pandemic? Can a Potential Pandemic Be Prevented? LONDON, April 8, 2013 /PRNewswire/ -- Bioradar UK Ltd. and Replikins Ltd. today announced that when the full H7N9 virus genomic sequences from the first lethal and surviving human cases of the current outbreak of H7N9 are available for analysis, hopefully within a week, their Bioradar Replikins FluForecast(®) software will be able to determine within 24 hours the likely...
BOSTON, Jan. 22, 2013 /PRNewswire/ -- Replikins Ltd. and Brain Research Associates announced today that specific conserved genomic Replikin peptide sequences for the first time have been found to be shared among different histological cancer types, permitting the seven day synthesis of new shared cancer vaccines. (Photo: http://photos.prnewswire.com/prnh/20130122/PH45996 ) Each of the shared Replikins was found to be present in multiple malignancies. The genomic Replikin(®)Count...
LONDON, Nov. 27, 2012 /PRNewswire/ -- The World Health Organization (WHO) last week reported that four new cases of SARS-like virus have been found in Saudi Arabia and Qatar, and the Department of Health in Singapore reported one additional case, adding to the two cases from the Middle East reported in late September. When the first two cases were reported, BioRadar UK Ltd., a biotechnology company focused on predicting and preventing viral pandemics, published data on October 5(th)...
LONDON, Oct. 5, 2012 /PRNewswire/ -- The identification of the virus responsible for a second case of SARS-like respiratory virus, "London1_novel CoV 2012", has raised concerns over the risk of the disease spreading (1). These concerns may be justified given the observed rise in virus's genomic Replikin(TM) Count. (Photo: http://photos.prnewswire.com/prnh/20121005/PH87818 ) An analysis of the current virus's genomic Replikin Count by Bioradar UK Ltd has revealed the Count to be...
LONDON, June 19, 2012 /PRNewswire/ -- The Foundation for Research on the Nervous System, Replikins Ltd., and Bioradar UK Ltd. today announced that over 100 new synthetic Replikins vaccines for infectious diseases and cancer are now available as a result of the discovery by scientists Drs. Samuel and Elenore Bogoch of the evolution of the genomic Replikins over time -- from ocean archaea to human cancer. A book on this subject will be released in September 2012. Peak Gene Replikin...
LONDON, Feb. 10, 2012 /PRNewswire/ -- Bioradar UK Ltd. reported today the fifth instance in which the specific strain and specific location of an influenza outbreak were predicted by the Replikins Count® (number of genomic Replikin peptides per 100 amino acids) alone, one to two years in advance of the outbreak. While the high-lethality H5N1 p B1 gene Replikins Count® increased globally from 2000 to 2010, uniquely in Cambodia it increased markedly in 2009. The previous four...
LONDON, Aug. 31, 2011 /PRNewswire/ -- The possible combination of influenza strains H1N1 (high infectivity) and H5N1 (high lethality) is a matter of global concern (1, 2). Bioradar UK Ltd announced today (3) first, that the Replikin Counts of the two virus strains have risen simultaneously, not seen previously. Additionally, the rise is to their highest levels in 50 years (H1N1, 16.7; H5N1, 23.3), and that clinical outbreaks of each strain are now occurring. These simultaneous conditions...
LONDON, Aug. 31, 2011 /PRNewswire/ -- The possible combination of influenza strains H1N1 (high infectivity) and H5N1 (high lethality) is a matter of global concern (1, 2). Bioradar UK Ltd announced today (3) first, that the Replikin Counts of the two virus strains have risen simultaneously, not seen previously. Additionally, the rise is to their highest levels in 50 years (H1N1, 16.7; H5N1, 23.3), and that clinical outbreaks of each strain are now occurring. These simultaneous conditions...
